Symbyax 25 mg/1

Olanzapine and fluoxetine hydrochloride, the active ingredient in Symbyax 25 mg/1, is an atypical antipsychotic and selective serotonin reuptake inhibitor presented as a 25 mg/1 capsule for oral use. It is used for the treatment of major depressive episodes associated with bipolar I disorder and for treatment-resistant depression in adults when prescribed as part of a defined regimen.

GNH USA supplies Symbyax 25 mg/1 as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Symbyax combines an antipsychotic and an antidepressant pathway to address specific mood disorders in adults.

- Major depressive disorder: used as adjunctive therapy in adults with treatment-resistant depression when other approaches have been inadequate. - Bipolar I disorder: used for depressive episodes associated with bipolar I disorder in adults. - Depressive symptoms in bipolar illness: helps manage depressive-phase symptoms under prescription-only supervision. - Treatment planning: may be selected when a clinician wants a single fixed-dose combination of olanzapine and fluoxetine rather than separate products.

Symbyax can cause adverse effects involving the nervous system, metabolism, and other organ systems.

Common Side Effects: - Somnolence: daytime sleepiness and reduced alertness may occur. - Weight gain: increased appetite and body weight are common with olanzapine-containing products. - Dry mouth: oral dryness may be reported. - Fatigue: tiredness or low energy can occur. - Dizziness: lightheadedness may be experienced. - Increased appetite: appetite changes may contribute to weight gain.

Serious or Rare Side Effects: - Suicidal thoughts or behavior: antidepressant-class warning, especially in younger patients. - Serotonin syndrome: agitation, fever, tremor, and autonomic instability may occur. - Hyperglycemia: blood sugar can rise, sometimes severely. - Neuroleptic malignant syndrome: rare but serious reaction with rigidity and fever. - Tardive dyskinesia: involuntary movements may develop with antipsychotic exposure.

Symbyax is prescription-only and should be used with clinical monitoring, especially during treatment initiation or dose changes.

- Psychiatric history: screen for bipolar disorder, suicidality, and prior medication reactions before use. - Metabolic monitoring: weight, glucose, and lipid changes may require periodic follow-up. - Sedation risk: avoid activities requiring full alertness until individual response is known. - Clinical supervision: do not stop or change therapy without prescriber guidance. - Pregnancy and lactation: use only after individualized risk-benefit assessment by a clinician. - Store at room temperature: keep in the original pack, protect from moisture.

Symbyax has clinically important interactions because it combines olanzapine and fluoxetine, each with its own interaction profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors: do not use together because of serotonin syndrome risk. - Pimozide: avoid due to potentially dangerous interaction with fluoxetine. - Thioridazine: avoid because fluoxetine can raise exposure and cardiac risk. - Coadministration with other serotonergic drugs: avoid when possible because serotonin toxicity may occur.

Moderate Interactions (Monitor Closely): - Alcohol: may worsen sedation and impaired coordination. - CNS depressants: additive drowsiness may occur with sedatives or sleep medicines. - Antidiabetic medicines: glucose control may need closer monitoring. - Anticoagulants or antiplatelets: bleeding risk may increase with fluoxetine.